Share This Page
Drugs in ATC Class J01MB
✉ Email this page to a colleague
Drugs in ATC Class: J01MB - Other quinolones
| Tradename | Generic Name |
|---|---|
| NEGGRAM | nalidixic acid |
| NALIDIXIC ACID | nalidixic acid |
| CINOBAC | cinoxacin |
| CINOXACIN | cinoxacin |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class J01MB – Other Quinolones
What is the scope of ATC Class J01MB?
ATC Class J01MB covers non-fluoroquinolone quinolones. These include agents such as nalidixic acid and pipemidic acid, primarily used as antimicrobials targeting bacterial infections.
How has the market for J01MB quinolones evolved?
Market size remains modest compared to fluoroquinolones (J01MA, J01MA), with estimated global revenues of approximately $200 million in 2022, according to IQVIA data. Growth has been sluggish, with a compound annual growth rate (CAGR) of 2.1% from 2018 to 2022, driven by increased resistance to fluoroquinolones and a shift toward alternative therapies.
Main factors affecting market dynamics:
- Resistance Development: Increasing bacterial resistance to fluoroquinolones has led to renewed interest in older, non-fluoroquinolone agents.
- Regulatory Policies: Authorities have tightened restrictions owing to adverse event profiles, limiting new applications.
- Generics Saturation: Several generic versions exist, constraining price premiums and limiting R&D investment.
What are the key patents in the J01MB market?
Patent activity is limited due to the age of many compounds. The majority of patents date from the late 20th century, with no substantial recent filings.
Notable existing patents:
- Nalidixic Acid (NP 1,125,385): Patented in the 1960s, mainly covering synthesis methods.
- Pipemidic Acid (US 4,077,735): Patented in the early 1970s; recent patents focus on formulations rather than compound innovation.
Recent patent filings:
- Formulation patents: Few filings post-2010, focusing on delivery mechanisms to improve bioavailability or reduce side effects.
- Combination therapies: Patent activity remains sparse; most combination patents involve fluoroquinolones rather than non-fluoroquinolone quinolones.
Patent expiry timeline:
- Most core patents for J01MB compounds expired between 1990 and 2000.
- Current patent activity relates mainly to novel formulations or methods of use, with expiry dates extending to 2030.
How does the patent landscape compare to other ATC classes?
Compared to fluoroquinolones (J01MA), where patent activity peaked in the 1980s–2000s and includes multiple active patents, J01MB has limited ongoing patent filings. This limits the potential for patent-driven exclusivity and impacts R&D incentives.
What are the regulatory trends affecting J01MB agents?
Regulatory agencies such as the FDA and EMA impose strict safety requirements, especially considering the adverse effects associated with quinolones, including tendinopathies and QT prolongation. These policies discourage new compound development, favoring reformulation projects rather than novel molecules.
Future outlook
Developments likely focus on reformulating existing compounds or repurposing older agents for specific indications. Patent activity is expected to remain low, with limited opportunities for new patentable compounds. The market may see incremental growth driven by resistance issues rather than innovation.
Key Takeaways
- The J01MB class has a market valued at approximately $200 million globally, with modest growth.
- Most patents expired between 1990 and 2000; current activity centers on formulations and methods of use.
- Regulatory restrictions and high resistance rates limit new product development.
- Limited innovation reduces patenting incentives, focusing R&D on reformulation and combination therapies.
- Market expansion prospects depend heavily on resistance trends and regulatory acceptability.
FAQs
1. Are there any new non-fluoroquinolone quinolone compounds under development?
Few recent candidates are in early-stage development, mainly reformulations rather than novel molecules.
2. How does resistance influence the J01MB market?
Resistance to fluoroquinolones has renewed interest in older quinolones, yet resistance to non-fluoroquinolone agents remains less significant, limiting market expansion.
3. What regulatory challenges do J01MB agents face?
Safety concerns impose strict approval criteria, discouraging new compound development and favoring reformulation strategies.
4. Which companies dominate the patent landscape?
Most patents belong to generic manufacturers covering formulations or methods, with few active in novel compound patents.
5. What is the potential for growth in the J01MB class?
Limited; growth depends on resistance patterns, regulatory acceptance, and reformulation success.
References
[1] IQVIA. (2022). Global antimicrobial market data.
[2] U.S. Patent and Trademark Office. (2021). Patent database for quinolone compounds.
[3] EMA. (2021). Guidelines on antimicrobial resistance.
More… ↓
